Sun Pharma Advanced Research Company Limited — Credit Ratings, 05-03-2025: Credit Rating- Revision

SPARC's credit rating has been downgraded to ACUITE AA- with a stable outlook. This action reflects a decline in operating performance due to reduced license fees and royalty income, coupled with setbacks from the Proseek study. Despite these challenges, SPARC's experienced management and strong R&D pipeline, bolstered by support from Shanghvi Finance Private Limited, provide a degree of stability.

Financial performance reveals significant deterioration, with operating income falling to ₹75.55 crore from ₹238.78 crore year-over-year, while net losses escalated to ₹387.22 crore compared to a loss of ₹222.58 crore in the prior period. This trend has continued into the current fiscal year, highlighting ongoing challenges in revenue generation.

Operational costs have surged, leading to tighter margins and necessitating capital investments with long gestation periods. The company's gearing has increased from 0.03x to 0.49x due to rising debt levels, reflecting operational stresses.

Going forward, SPARC's strategic focus must include effective cost management, timely product development, and navigating the regulatory landscape. Investor sentiment may remain cautious, particularly given the operating hurdles. A "hold" perspective seems prudent as SPARC endeavors to stabilize its financial situation and leverage parent company support for recovery initiatives.